Table 4 Characteristics of the included studies in the meta-analysis
Studies | Country | Recruited period | No. of patients | % of ILC/IDC | Stage of disease | Tissue processing | Antibody/Cutoff | % of E-cad expression | Molecular subtypes | |
|---|---|---|---|---|---|---|---|---|---|---|
Non-TNBC | TNBC | |||||||||
Aleskandarany et al. [27] | UK | 1990–1998 | 1035 | 0/70% | NR | TMA | C3865/>100 H-scorea | 50% (519/1035) | 808 (luminal 652, HER2-enriched 156) | 197 |
Choi et al. [11] | Korea | 2009–2011 | 382 of 438 | 0/91% (397/438) | I–IV | TMA | NCH-38/10% | 65% (247/382) | 313 (luminal A 177, luminal B 96, HER2-enriched 40) | 69 |
Jeong et al. [17] | Korea | 1992–2006 | 492 | 0.6/97% | I–IV | TMA | SPM471/NR | 85% (418/492) | 363 (luminal 221, HER2-enriched 142) | 102 |
Kashiwagi et al. [16] | Japan | 2000–2006 | 574 | 0/83% | I–III | Whole slide section | NCH-38/≥30% | 59% (336/574) | 451 | 123 |
Liu et al. [25] | China | 2000–2004 | 441 | NR | I–IV | Whole slide section | Abcam/>10% | 63% (276/441) | 264 (luminal A 84, luminal B 90, HER2-enriched 90) | 177 |
Mahler-Araujo et al. [12] | UK | NR | 180 of 245 | 0/87% (156/180) | NR | TMA | HECD-1/≥50% | 65% (142/217) | 154 | 26 |
Pang et al. [26] | China | 2001–2002 | 170 | 9%/78% | I–III | Whole slide section | Santa/>10% | 36% (61/170) | 129 | 41 |
Pomp et al. [28] | Switzerland | 1991–2011 | 617 | 15%(87/565)/80% (454/565) | I–IV | TMA | EP700Y/>50% | 88% (527/598) | 478 (luminal 439, HER2-enriched 39) | 120 |
Rakha et al. [22] | UK | 1986–1998 | 1711 of 1722 | NR/80% (1378/1722) | I–IV | TMA | HECD-1/>100 H-score | 46% (795/1711) | 1436 | 275 |
Sarrio et al. [23] | Spain | 1993–2001 | 491 | 5/93% | NR | TMA | 4A2C7/≥50% | 45% (221/491) | 399 | 64 |
Wu et al. [24] | China | 2000–2006 | 382 | 2%/93% | I–IV | Whole slide section | 4A2C7/≥50% | 79% (301/382) | 341 (luminal A 232, luminal B 45, HER2-enriched 64) | 41 |
This study | China | 2011–2014 | 156 | 0/100% | I–II | Whole slide section | 4A2C7/≥50% | 83% (129/156) | 118 (luminal A 30, luminal B 74, HER2-enriched 14) | 38 |